Uni-Bio Science Group Limited EBIT

As of the most recent data (June 2026), 0690.HK shows a EBIT of $160M. That compares with $180M in the prior-year period — down 9.1% year over year. That is below the Healthcare sector average of $130B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 0690.HK's EBIT is now $160M (was $180M) — a 9.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Uni-Bio Science Group Limited is outperforming or lagging.

The Healthcare sector average EBIT is about $130B. Uni-Bio Science Group Limited is at $160M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how 0690.HK stacks up against individual peers as well.

Tracking 0690.HK's ebit over time shows whether Uni-Bio Science Group Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $160M That compares with $180M in the prior-year period — down 9.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Uni-Bio Science Group Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $160M) with ownership activity and broader fundamentals.